Cyramza
Cyramza ingredients
| Active ingredient | Strength |
|---|---|
| Ramucirumab | 10 mg/mL |
What Cyramza is used for
The FDA lists the approved uses on the official label (below). In the EU, ramucirumab is approved as Cyramza for:
Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate. Colorectal cancer Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. Non-small cell lung cancer Cyramza in combination…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Cyramza
- Generic name
- Ramucirumab
- Made by
- Eli Lilly and Company
- Forms
- Solution
- Given
- Intravenous
- Drug class
- Vascular Endothelial Growth Factor Receptor 2 Antagonist
- FDA approval
- Biologic licence (BLA) BLA125477
- On the US market since
- 2014
Official information
- Cyramza prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ramucirumab)
In India
- Ramucirumab: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Cyramza?
Cyramza (Ramucirumab) is a cancer medicine made by Eli Lilly and Company, approved by the US FDA.
What are the ingredients of Cyramza?
Cyramza contains Ramucirumab (10 mg/mL).
Is Cyramza approved in Europe?
The same active substance is approved in the EU as Cyramza.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA